Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
about
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.Time-dependent endpoints as predictors of overall survival in multiple myelomaProgression-free survival as a potential surrogate for overall survival in metastatic breast cancer.Detecting an overall survival benefit that is derived from progression-free survivalIn the end what matters most? A review of clinical endpoints in advanced breast cancer.Endpoints in advanced breast cancer: methodological aspects & clinical implications.International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Progression-free survival as a surrogate endpoint in advanced breast cancerRelationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trialTargeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Clinical significance of post-progression survival in lung cancerProgression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Q21146752-1B2017DE-5CD3-4711-8082-CFCB60C1CB78Q30538040-B98341E3-CD61-4C9F-9368-97DAA8C49B2DQ33800697-FAA29AE2-FC45-4C0D-B0CE-D49218EF2939Q34063143-2CF57168-E043-4079-B2B3-66A9CEA38A98Q35584322-67611534-96C0-435B-9747-39E14E174F2BQ35611036-72F8C2B9-2438-4E6E-B714-C05A31316DD0Q35820247-12A21368-8B3B-4EB7-9164-7DDC74343F41Q35825822-67C321E7-297B-4CD3-997B-9458FA38C672Q36349459-E76E5D86-1F64-4740-ABA5-1DCF9A8758A1Q36552307-75B0BDE7-31A3-4BDE-B9B4-4D6C46E4C573Q36977501-ACFB1CFF-0B20-487F-A47D-29EA4F4F2A54Q37246407-78EEE1CE-BE89-4F88-91C7-FA67065C0726Q37477489-9E82B348-2E80-4ED7-BF23-5698DD1A920FQ37630084-A88EF362-2C90-44A8-89BB-EBAFDB70A604Q37760357-E6DF1EE9-AE7C-4167-B224-53996A84FB0EQ37901096-D04C90DA-8007-4497-B835-45E9AC66F954Q38259501-78C11543-535C-4365-B4D3-4369B9A45055Q38669447-C5ADAB72-3DEE-496D-B062-5CBE64C7B4B8Q39778923-7AE20168-B6A6-48B5-9706-FE35D7571722Q39933767-E1CC578D-3614-4068-A733-A4CC7E095346Q44789980-5491855F-E218-4D62-AF9F-F76DEB3A8BD7Q53717818-EE94A26A-2F93-4C53-9399-295B856B7898
P2860
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Surrogate markers and survival ...... apy for advanced breast cancer
@ast
Surrogate markers and survival ...... apy for advanced breast cancer
@en
type
label
Surrogate markers and survival ...... apy for advanced breast cancer
@ast
Surrogate markers and survival ...... apy for advanced breast cancer
@en
prefLabel
Surrogate markers and survival ...... apy for advanced breast cancer
@ast
Surrogate markers and survival ...... apy for advanced breast cancer
@en
P2093
P2860
P356
P1476
Surrogate markers and survival ...... apy for advanced breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602858
P407
P577
2005-11-01T00:00:00Z